Review of vedolizumab for the treatment of ulcerative colitis

Lau, Michelle Sy; Tsai, Her Hsin

doi:10.4292/wjgpt.v7.i1.107

Cited by 14 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common adverse reactions seen with vedolizumab are infusion reactions and infections due to immunomodulation. 54 Safety data showed a similar adverse reaction rate to placebo. 55 Malignancies were reported in 0.4% of those treated with vedolizumab, but the long-term exposure was limited.…”

Section: Discussionmentioning

confidence: 83%

“… 53 Since integrin α4β7 receptors are found more in the gut epithelium, vedolizumab is indicated currently for moderate-to-severe CD and UC. 54 Clinical trials in pediatric population are also ongoing for UC and CD since November 2017. 55 , 56 The agent is available in the market as 300 mg of lyophilized cake in a single-dose 20 mL vial for reconstitution.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Rawla

Sunkara

Raj

2018

JIR

119

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily since 1990, and so the number of agents used in their treatment. Biologics that are derived partly or completely from living biological sources such as animals and humans have become widely available, which provide therapeutic benefits to the IBD patients. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab) are approved for use in IBD. Biosimilars of infliximab and adalimumab are also available for the treatment of IBD. This review summarizes the clinical pharmacology, studies leading to their approval, overall indications and their use in IBD, usage in pregnancy and lactation, and the adverse effects of these agents. This review also summarizes the recent advances and future perspectives specific to biologics and biosimilars in IBD.

show abstract

Section: Discussionmentioning

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Rawla

Sunkara

Raj

2018

JIR

119

View full text Add to dashboard Cite

show abstract

“…Common reported adverse events with vedolizumab include headache, nausea, abdominal pain, fatigue and nasopharyngitis, although these did not occur in the registration studies any more frequently than with placebo (except nasopharyngitis). There have been no reports of progressive multifocal leukoencephalopathy with vedolizumab unlike natalizumab, which was a less selective anti-integrin agent 13 14…”

Section: Discussionmentioning

confidence: 99%

Vedolizumab: a novel treatment for ipilimumab-induced colitis

Hsieh¹,

Ferman

Brown

et al. 2016

BMJ Case Reports

View full text Add to dashboard Cite

Use of the immune checkpoint inhibitors, ipilimumab and nivolumab, has revolutionised treatment in patients with metastatic melanoma. However, these drugs can cause an autoimmune enterocolitis, with diarrhoea as the presenting symptom. This is conventionally managed by prompt institution of corticosteroid therapy if moderate diarrhoea (3-6 times/day; grade 2) is present for >5 days or if diarrhoea is severe (>6 times/day; grade 3). We report a case of steroid-dependent ipilimumab-induced colitis successfully treated with vedolizumab (an inhibitor of memory T-cell trafficking to the gut), after which complete withdrawal of corticosteroid was achieved. Hence, vedolizumab warrants further evaluation as a potential novel treatment of ipilimumab-induced colitis.

show abstract

“…Vedolizumab is a humanized anti-integrin antibody selective to its a4b7 heterodimer, and exerts its action in a rather specific mechanism by limiting both B-and T-cell lymphocyte fixation on the intestinal vascular endothelial cells and consequent migration to the lamina propria and tissue cells [26,39].…”

Section: Mechanisms and Drugs Involved In Mucosal Healing (Mh)mentioning

confidence: 99%

Mucosal Healing in Ulcerative Colitis: A Comprehensive Review

Carvalho

Cotter

2017

Drugs

120

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of remission and periods of relapse. Patients often present with symptoms such as rectal bleeding, diarrhea and weight loss, and may require hospitalization and even colectomy. Long-term complications of UC include decreased quality of life and productivity and an increased risk of colorectal cancer. Mucosal healing (MH) has gained progressive importance in the management of UC patients. In this article, we review the endoscopic findings that define both mucosal injury and MH, and the strengths and limitations of the scoring systems currently available in clinical practice. The basic mechanisms behind colonic injury and MH are covered, highlighting the pathways through which different drugs exert their effect towards reducing inflammation and promoting epithelial repair. A comprehensive review of the evidence for approved drugs for UC to achieve and maintain MH is provided, including a section on the pharmacokinetics of anti-tumor necrosis factor (TNF)-α drugs. Currently approved drugs with proven efficacy in achieving MH in UC include salicylates, corticosteroids (induction only), calcineurin inhibitors (induction only), thiopurines, vedolizumab and anti-TNFα drugs (infliximab, adalimumab, and golimumab). MH is of crucial relevance in the outcomes of UC, resulting in lower incidences of clinical relapse, the need for hospitalization and surgery, as well as reduced rates of dysplasia and colorectal cancer. Finally, we present recent evidence towards the need for a more strict definition of complete MH as the preferred endpoint for UC patients, using a combination of both endoscopic and histological findings.

show abstract

Review of vedolizumab for the treatment of ulcerative colitis

Cited by 14 publications

References 14 publications

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Vedolizumab: a novel treatment for ipilimumab-induced colitis

Mucosal Healing in Ulcerative Colitis: A Comprehensive Review

Contact Info

Product

Resources

About